Gulf Pharmaceutical
Gulf Pharmaceutical Industries, commonly known as Julphar, is a leading pharmaceutical company headquartered in the United Arab Emirates (AE). Established in 1980, Julphar has grown to become a prominent player in the Middle East and North Africa (MENA) region, focusing on the development, manufacturing, and distribution of high-quality pharmaceutical products. With a diverse portfolio that includes prescription medications, over-the-counter products, and biotechnology solutions, Julphar is renowned for its commitment to innovation and quality. The company has achieved significant milestones, including the establishment of state-of-the-art manufacturing facilities and a robust research and development programme. Julphar's dedication to excellence has positioned it as a trusted name in the pharmaceutical industry, contributing to improved healthcare outcomes across its operational regions.
DitchCarbon Score
How does Gulf Pharmaceutical's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Gulf Pharmaceutical's score of 20 is higher than 73% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Gulf Pharmaceutical's reported carbon emissions
In 2023, Gulf Pharmaceutical reported total carbon emissions of approximately 35,100 kg CO2e, comprising about 6,300 kg CO2e from Scope 1 and about 29,400 kg CO2e from Scope 2 emissions. This marks a slight decrease from 2022, where emissions were about 35,800 kg CO2e. Over the years, the company has shown a trend of reducing its emissions, with a notable drop from approximately 34,300,000 kg CO2e in 2020 to 35,100 kg CO2e in 2023. Despite these reductions, Gulf Pharmaceutical has not publicly committed to specific reduction targets or initiatives, nor have they aligned with the Science Based Targets initiative (SBTi). The absence of formal climate pledges suggests that while the company is making progress in reducing its emissions, there is potential for more structured commitments to enhance their climate strategy. Overall, Gulf Pharmaceutical's emissions data reflects a commitment to reducing their carbon footprint, although further transparency and formal targets could strengthen their climate commitments in the pharmaceutical industry.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Get Started| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 8,417,000 | 0,000,000 | 0,000,000 | 0,000 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 33,350,000 | 00,000,000 | 00,000,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 3 | - | - | - | - | - | - | - |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Gulf Pharmaceutical is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
